This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jo Alene Dolan, PhD; Jess Amchin, MD, JD; Dominick Albano, RPh, MBA
Wyeth-Ayerst Laboratories Philadelphia, Pa

JAMA. 1996;276(15):1220-1221.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—The letter from Drs Schenck and Mahowald that discusses the potential for serotonin syndrome when using dexfenfluramine hydrochloride (Redux) with other serotoninergic agents warrants additional comment. The authors neglected to point out that the serotonin syndrome appears to be rare, even among patients taking serotoninergic drug combinations.^1,2 Without their making this point, readers may be misled by their suggestion that large numbers of people are at risk for this syndrome. Serotonin syndrome has been reported more often with certain drug combinations such as MAOIs used with serotoninergic agents and is reported less frequently with other drug combinations.¹ By not making this distinction, it appears that all the agents cited by the authors represent a similar risk when used with dexfenfluramine.

The lack of reported cases of serotonin syndrome in patients receiving dexfenfluramine alone or in combination with other agents is reassuring, especially in view of its widespread clinical . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?